Opana ER

Express Scripts Kicks Out EpiPen Competitors
Express Scripts Kicks Out EpiPen CompetitorsBig changes for EpiPen and more in Express Scripts’ formulary.
FDA to drug maker: Pull opioid pain drugPotential public health consquences prompts FDA to request removal of opioid pain medication.
FDA Orders Stop Sale of PainkillerThe first opioid taken off the shelves because of potential abuse.
Balancing opioid benefits, dangersOpioids are powerful clinical tools that effectively treat pain and have a place in therapy, but it can be difficult to manage the dangers. Here's a look at some of the abuse-deterrent drugs on the horizon.
Endo’s petition to block generic forms of Opana ER thwarted by FDAComing on the heels of FDA's denial of generic forms of OxyContin, the ruling triggers speculation about overall FDA strategy
FDA denies request to block generic versions of Opana ERFDA has denied Endo Health Solutions' petition to block generic forms of its opioid agonist Opana ER, which contains oxymorphone. FDA’s decision comes just weeks after it nixed generic OxyContin and approved abuse-deterrent labeling for reformulated OxyContin (Purdue Pharma).
TTP risk seen with intravenous abuse of Opana ERIntravenous abuse of Opana ER may be at risk of thrombotic thrombocytopenic purpura according to a report published in MMWR.